A Phase I/IIa Study of EF-009 in Patients with Pancreatic Cancer

NCT04381130 · clinicaltrials.gov ↗

PHASE1,PHASE2

Phase

NOT_YET_RECRUITING

Status

30

Enrollment

INDUSTRY

Sponsor class

Conditions

Pancreatic Cancer

Interventions

DRUG: EF-009

Sponsor

Everfront Biotech Co., Ltd.